Make safer calls, faster
Evaluate safety, stratify patients, and pressure-test clinical decisions with evidence pulled into one decision-ready workflow.
Interaction risk, screened up front
See how EMET supports clinical teams focused on therapy safety, evidence review, and decision support.
Clinical capabilities
Explore a range of sample prompts and representative outputs from EMET across the workflows below.
Drug-Drug Interaction Assessment
Our new JAK2 inhibitor will be co-administered with warfarin, omeprazole, sertraline, and metoprolol in elderly oncology patients. Run a comprehensive DDI screen and flag major interactions with mechanistic explanation.
Clinical Target Intelligence
Assess the clinical evidence and safety profile for KRAS G12C inhibitors in non-small cell lung cancer - summarize approved therapies, ongoing trials, known resistance mechanisms, and any pharmacogenomic considerations.
Adverse Event Signal Detection
Analyse FAERS data for the SGLT2 inhibitor class (canagliflozin, dapagliflozin, empagliflozin). Quantify the signal strength for Fournier's gangrene, DKA, and amputation risk using PRR/ROR statistics, show temporal trends since approval, and compare signal magnitude across agents.
Biomarker Discovery & Patient Stratification
Identify genomic and transcriptomic biomarkers that could stratify HER2-low breast cancer patients most likely to respond to trastuzumab deruxtecan (T-DXd), and assess the evidence supporting each biomarker's clinical utility.
Comparative Drug Safety Profiling
Generate a comprehensive comparative safety profile for all three approved CDK4/6 inhibitors - palbociclib, ribociclib, and abemaciclib - across FAERS signal data, FDA label warnings, and Grade 3/4 AE rates from their pivotal Phase III trials. Identify any meaningful safety differentiation.
Frequently asked questions
Drug programs fail when biology is misunderstood. EMET exists to close that gap — before it closes your pipeline.
Start free trial